Harbingers of Things to Come in Gene Therapy
By Josh P. Roberts,
Genetic Engineering & Biotechnology News
| 04. 02. 2021
Photo by CDC on Unsplash
It is one thing to anticipate what gene therapy will look like in 5 years, let alone 10. The deeper we peer into the crystal ball, the less we can rely on what we see. So, let us put scrying and intuition aside. Instead, let us take a close look at gene therapy’s present state and how it has come to be. We will identify the forces behind gene therapy’s recent advances—as well as newly emergent forces—and we will keep in mind that these forces will likely wax and wane. Then we will be better able to predict what gene therapy will look like in the near future (or even the not-so-near future).
Vector improvements
Gene therapy can be divided into in vivo and ex vivo treatments. In the former, genetic material is delivered directly to the host by means of a vector such as a virus or nanoparticle. In cell-based gene therapies, on the other hand, genetic material is introduced to a patient’s cells ex vivo, and then the modified cells are returned to...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...